Minoxidil Studies: Oral Evidence Graded by GRADE

What the studies can establish

GRADE sorts a body of evidence into high, moderate, low or very low certainty. The evidence for low-dose oral minoxidil is a set of small randomized comparisons against topical minoxidil plus uncontrolled observational data [1][2][4]. A review of 17 studies covering 634 patients concluded that oral minoxidil appeared effective and well tolerated in healthy patients who struggle with topical use, and that larger randomized dose-comparison studies were needed [7].

What the randomized trials found

The largest head-to-head trial enrolled 90 men aged 18 to 55 at one clinic in Brazil; 68 completed. It compared oral minoxidil 5 mg daily with 1 mL of topical 5% twice daily for 24 weeks, each with a matching placebo. Between-group differences were not statistically significant: frontal terminal hair density 3.1 hairs/cm2 (95% CI -18.2 to 21.5; P=0.27) and vertex density 23.4 hairs/cm2 (95% CI -0.3 to 43.0; P=0.09) [1].

A second trial of 65 patients compared 5% topical solution with oral minoxidil 1 mg daily for 6 months; both improved hair diameter (P<0.001) with no significant difference between them [2].

A 2020 trial in women also compared oral minoxidil 1 mg with topical 5% for female-pattern hair loss. Its PubMed record has no abstract, so no results are stated here [8].

What the safety and dose-response data show

In a retrospective multicenter study of 1,404 patients (943 women, 461 men; mean age 43) treated at least 3 months with no control group, hypertrichosis occurred in 15.1% and led to withdrawal in 14 patients (0.5%). Lightheadedness 1.7%, fluid retention 1.3% and tachycardia 0.9% were next, and 29 patients (1.2%) stopped treatment because of systemic effects. No life-threatening adverse effects were observed [4].

A 2025 meta-analysis of uncontrolled studies using 5 mg/day or less found no significant change in systolic or diastolic blood pressure, and a heart rate increase of 2.67 beats per minute (95% CI 0.34 to 5.01). Hypotensive symptoms were reported in 119 patients (5.0%), with no hypotensive episodes [6].

A meta-regression of six observational studies associated each additional 1 mg/day with total hair density of +47.1 hairs/cm2 at 6 months, hypertrichosis risk of +17.9% and cardiovascular adverse event risk of +4.8%, described as associations rather than causation [3].

What the label says

The tablet label carries a boxed warning and reserves minoxidil for hypertensive patients who do not respond to maximum doses of a diuretic plus two other antihypertensives. It warns about pericardial effusion, occasionally progressing to tamponade, about angina that may worsen, and about salt and water retention that can lead to heart failure [5]. The label says a beta blocker is usually given to help prevent a rapid heart rate and increased cardiac workload, while a diuretic is usually given to help prevent serious fluid accumulation [5].

Label dosing starts at 5 mg once daily, with a usual effective range of 10 to 40 mg/day and a maximum of 100 mg/day. The 1 mg and 5 mg doses used in the hair-loss trials are off-label; 1 mg is well below the label's range, and 5 mg is the label's starting dose for hypertension [5].